Editorial: Impact of IL-28B SNPs on control of hepatitis C virus infection: A genome-wide association study

Expert Review of Anti-Infective Therapy

Volumn 8, Issue 5, 2010, Pages 497-499

  Imazeki, Fumio ^a   Yokosuka, Osamu ^a   Omata, Masao ^b  

^a CHIBA UNIVERSITY   (Japan)

^b Yamanashi Prefectural Central Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 28B; MESSENGER RNA; PEGINTERFERON; RIBAVIRIN; ANTIVIRUS AGENT; IL28B PROTEIN, HUMAN; INTERFERON; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE;

DRUG EFFICACY; EDITORIAL; ERADICATION THERAPY; GENE EXPRESSION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HUMAN; INFECTION CONTROL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; METABOLISM; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GENOME-WIDE ASSOCIATION STUDY; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; INTERLEUKINS; POLYETHYLENE GLYCOLS; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TREATMENT OUTCOME;

EID: 77952271411     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/eri.10.30     Document Type: Editorial

References (15)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558-567 (2005).
2. Choo QL, Kuo G, Weiner AJ et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244, 359-362 (1989).
3. Hadziyannis SJ, Sette H Jr, Morgan TR et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 140, 346-355 (2004).
4. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
5. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461, 399-401 (2009).
6. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 41, 1100-1104 (2009).
7. Rauch A, Kutalik Z, Descombes P et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure - a genome-wide association study. Gastroenterology 138(4), 1338-1345 (2010).
8. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-a and ribavirin therapy for chronic hepatitis C. Nat. Genet. 41, 1105-1109 (2009).
9. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and to spontaneous clearance of hepatitis C virus. Nature 461, 798-801 (2009).
10. Kotenko SV, Gallagher G, Baurin VV et al. IFN-l mediate antiviral protection through a distinct class II cytokine receptor complex. Nat. Immunol. 4, 69-77 (2003).
11. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 4, 63-68 (2003).
12. Li M, Liu X, Zhou Y et al. Interferon-ls: the modulators of antivirus, antitumor, and immune responses. J. Leukoc. Biol. 86, 23-32 (2009).
13. Marcello T, Grakoui A, Brba-Spaeth G et al. Interferons a and l inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131, 1887-1898 (2006).
14. Pagliaccetti NE, Eduardo R, Kleinstein SH et al. Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication. J. Biol. Chem. 283, 30079-30089 (2008).
15. Shiffnan M, Lawitz E, Zaman A. PEG-IFN-l: antiviral activity and safety profile in a 4-week Phase 1b study in relapsed genotype 1 hepatitis C infection. J. Hepatol. 50, S237 (2009).